COVID-19 and Substance Use Compound Challenges
Webinar participants discuss best practices for pharmacists with patients contending with both issues.
Related Articles
Gap in Medicaid Impacts Access to Services for Justice-Involved Patients
Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases
Positive Data Demonstrates Gepotidacin is Non-Inferior to Alternative Treatment in GC
In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.
FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease
The primary endpoint of the study was clinical remission at week 52 with vedolizumab
Study: The Role of Vitamin A in Wound Repair
Retinoic acid, an active form of vitamin A, is crucial for the stem cells to depart lineage plasticity which get separated into hair cells or…
RSV Vaccine Could Prevent Increased Risk of Disease Among Individuals Aged 18 to 59
The results displayed well tolerability and safety with Abrysvo, meeting the study’s co-primary endpoint of immunogenicity and primary safety
Middletown Pharmacy and Wellness Staff Care for the Community
Tara Schneider, PharmD, and her husband, Chuck Schneider, MBA, offer expanded clinical services in their Louisville, Kentucky, pharmacy.
Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years
The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
Climate Change Increases Rate of Infectious Diseases, Expert Says
Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.
Identifying and Screening for Hepatic Encephalopathy Risk Factors
Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors…
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.